Halima H. Al Shuaili

Dr. Halima H. Al Shuaili

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAbdullah M Al Alawi
Abdullah M Al Alawi
HSHalima H. Al Shuaili
Halima H. Al Shuaili
KAKhalid Al-Naamani
Khalid Al-Naamani
ZAZakariya Rashid AL-Naamani
Zakariya Rashid AL-Naamani
Said A. Al-BusafiSaid A. Al-Busafi
Said A. Al-Busafi
Background: Chronic hepatitis C (HCV) infection presents global health challenges with significant morbidity and mortality implications. Successfully treating patients with cirrhosis may lead to mortality rates comparable to the general population. This study aims to utilize machine learning techniques to create predictive mortality models for individuals with chronic HCV infections. Methods: Data from chronic HCV patients at Sultan Qaboos University Hospital (2009–2017) underwent analysis. Data pre-processing handled missing values and scaled features using Python via Anaconda. Model training involved SelectKBest feature selection and algorithms such as logistic regression, random forest, gradient boosting, and SVM. The evaluation included diverse metrics, with 5-fold cross-validation, ensuring consistent performance assessment. Results: A cohort of 702 patients meeting the eligibility criteria, predominantly male, with a median age of 47, was analyzed across a follow-up period of 97.4 months. Survival probabilities at 12, 36, and 120 months were 90.0%, 84.0%, and 73.0%, respectively. Ten key features selected for mortality prediction included hemoglobin levels, alanine aminotransferase, comorbidities, HCV genotype, coinfections, follow-up duration, and treatment response. Machine learning models, including the logistic regression, random forest, gradient boosting, and support vector machine models, showed high discriminatory power, with logistic regression consistently achieving an AUC value of 0.929. Factors associated with increased mortality risk included cardiovascular diseases, coinfections, and failure to achieve a SVR, while lower ALT levels and specific HCV genotypes were linked to better survival outcomes. Conclusions: This study presents the use of machine learning models to predict mortality in chronic HCV patients, providing crucial insights for risk assessment and tailored treatments. Further validation and refinement of these models are essential to enhance their clinical utility, optimize patient care, and improve outcomes for individuals with chronic HCV infections.

10 January 2018 in Sultan Qaboos University Medical Journal
Verified
Journal Article
Open access
PDF file
SASaid A. Al-Busafi
Said A. Al-Busafi
HSHalima H. Al Shuaili
Halima H. Al Shuaili
HOHeba Omar
Heba Omar
HAHaifa Al-Zuhaibi
Haifa Al-Zuhaibi
LJL. Jeyaseelan
L. Jeyaseelan
KAKhalid Al-Naamani
Khalid Al-Naamani
Objectives: Chronic hepatitis C (CHC) is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. However, there is a lack of data regarding the epidemiology of CHC in Oman. This study aimed to describe the clinicopathological characteristics and outcomes of CHC-infected patients at a tertiary care hospital in Oman. Methods: This retrospective descriptive hospital-based study included all CHC-infected patients who presented to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between January 2010 and December 2015. The baseline demographic, clinical, laboratory and radiological data of the patients were analysed. Results: A total of 603 CHC-infected patients were identified during the study period; of these, 65.8% were male and the mean age was 44.8 ± 16.5 years. The main risk factors associated with CHC infection were intravenous drug abuse (23.9%) and a history of blood transfusions (20.7%). The most prevalent virus genotypes were 1 and 3 (44.0% and 35.1%, respectively). Upon initial presentation, 33.0% of the cohort had liver cirrhosis; of these, 48.7% had decompensated cirrhosis and 23.1% had HCCs. Liver transplantation was only performed for 7.5% of the cirrhosis patients, mostly as a curative treatment for HCC. Conclusion: The implementation of national policies to prevent hepatitis C transmission and encourage the early screening of at-risk patients is recommended to reduce the burden and consequences of this disease in Oman.

12 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Said A. Al-BusafiSaid A. Al-Busafi
Said A. Al-Busafi
AAAmna Said AlBalushi
Amna Said AlBalushi
HSHalima H. Al Shuaili
Halima H. Al Shuaili
DMDalia A. Mahmood
Dalia A. Mahmood
AAAbdullah M Al Alawi
Abdullah M Al Alawi
Background: Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are significant causes of chronic liver disease, potentially leading to liver cirrhosis and hepatocellular carcinoma. Moreover, the coexistence of CHB and NAFLD is increasingly common, although the relationship between NAFLD and inactive CHB infection remains poorly understood. Objectives: This study aimed to investigate the prevalence of NAFLD among patients with inactive CHB, identify risk factors for NAFLD, and determine predictors of significant fibrosis in these patients. Methods: This single-center cross-sectional study targeted patients with inactive CHB at Sultan Qaboos University Hospital from January 2010 to November 2021. Results: A total of 425 patients with inactive CHB were identified, of which 53.1% were male and 62.6% were aged 40–60 years. The prevalence of NAFLD was 47.8%. Various independent factors were associated with NAFLD, including type 2 diabetes mellitus, elevated low-density lipoprotein levels, high hemoglobin levels, low platelet counts, and normal alpha-fetoprotein levels. Significant associations were noted between NAFLD and significant fibrosis, with 10.5% of CHB patients with NAFLD exhibiting significant fibrosis compared to 1.4% of those without NAFLD. Other significant parameters included male gender, increased age, high alanine transaminase levels, elevated hemoglobin, and decreased platelet levels. Conclusions: The high prevalence of NAFLD in patients with inactive CHB and its associations with increased fibrosis and cirrhosis risk underscore the need for comprehensive management strategies for these patients.

5 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
KAKhalid Al-Naamani
Khalid Al-Naamani
HOHeba Omar
Heba Omar
Said A. Al-BusafiSaid A. Al-Busafi
Said A. Al-Busafi
HSHalima H. Al Shuaili
Halima H. Al Shuaili
ZAZakariya Rashid AL-Naamani
Zakariya Rashid AL-Naamani
HAHaifa Saif Alzuhaibi
Haifa Saif Alzuhaibi
Background: The advent of direct-acting antiviral (DAA) therapy has revolutionized the treatment landscape of the hepatitis C virus (HCV) infection. This study aimed to provide a comprehensive research study of the real-world effectiveness and safety of DAA treatment, representing the first study conducted in the Omani population. Methods: A cross-sectional study was conducted including 375 HCV patients with different genotypes, treated using different DAA regimens, with or without ribavirin, between January 2012 and December 2020 at the Sultan Qaboos University Hospital and the medical city for military and security services, two tertiary hospitals in Muscat, Oman. The rate of sustained virologic response 12 weeks after completing the regimen (SVR-12) was analyzed as the primary outcome. Secondary outcomes included treatment safety and adverse events related to DAA therapy, as reported by patients and treating physicians. Results: A total of 375 patients were included in the study, with a mean age of 47.3 ± 15.4 years. Most were male (59.2%) and treatment-naïve (71.7%). The prevalence of liver cirrhosis was 19.7%, while 4.0% had hepatocellular carcinoma (HCC). The SVR-12 rate among treatment-naïve and treatment-experienced patients was 95.0% and 93.4%, respectively. Several parameters were associated with DAA treatment failure, including liver cirrhosis (p = 0.004) and active HCC (p = 0.009). Following SVR-12, significant improvements were observed in alanine transaminase, bilirubin, and albumin levels, Fibrosis-4 Index, and liver stiffness measurements compared to baseline (p <0.001 each). No significant adverse effects were reported. Conclusions: Based on our real-world experience, DAAs are highly effective in treating patients with HCV infection in Oman, with an excellent tolerability and safety profile.

20 September 2023 in Saudi Journal of Gastroenterology
Verified
Journal Article
Open access
HSHalima H. Al Shuaili
Halima H. Al Shuaili
Said A. Al-BusafiSaid A. Al-Busafi
Said A. Al-Busafi
KAKhalid Al-Naamani
Khalid Al-Naamani
ZAZakariya Al-Naamani
Zakariya Al-Naamani
Background: Chronic hepatitis C (CHC) is a leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide. This study aimed to determine rates and predictors of survival among Omani patients with CHC at a tertiary hospital in Muscat, Oman. Methods: This ambidirectional cohort study included all CHC patients who presented to the Sultan Qaboos University Hospital between January 2009 and December 2017. Baseline demographic, clinical, laboratory, and radiological data were analyzed. Patients were followed-up until death or the endpoint of the study (April 2022) to determine survival and associations with other parameters. Results: A total of 702 CHC patients were included, of which 398 (56.7%) were under 50 years of age and 477 (67.9%) were male. Overall, 180 patients (25.6%) died by the study endpoint. The mean duration of follow-up was 93.3 ± 48.0 months. The 5-year survival rate was estimated to be 80.5%, while the 10-year survival was 73%. Sustained virological response and the absence of diabetes mellitus, chronic kidney disease, HCC, or other malignancies were associated with significantly better overall survival. The 3- and 5-year survival rate of patients with hepatitis C virus (HCV)-related HCC was 46.5% and 27.6%, respectively, with a median survival of 29.5 months. Co-infection with hepatitis B was associated with poor survival among this subgroup; conversely, early HCV screening and the presence of a single HCC lesion were associated with better overall survival. Conclusions: National policies for early CHC screening and rapid treatment are needed to improve survival rates in this population.

Verified
Journal Article
Open access
PDF file
AAAbdullah M Al Alawi
Abdullah M Al Alawi
AAAmna Said AlBalushi
Amna Said AlBalushi
HSHalima H. Al Shuaili
Halima H. Al Shuaili
DMDalia A. Mahmood
Dalia A. Mahmood
Said A. Al-BusafiSaid A. Al-Busafi
Said A. Al-Busafi
Background/Objectives: Non-alcoholic fatty liver disease (NAFLD) represents significant health challenges, especially among patients with chronic hepatitis B (CHB). This study uses machine learning models to predict NAFLD in patients with inactive CHB. It builds on previous research by employing classification algorithms to analyze demographic, clinical, and laboratory data to identify NAFLD predictors. Methods: A single-center cross-sectional study was conducted, including 450 inactive CHB patients from Sultan Qaboos University Hospital. Five ML models were developed: Logistic Regression, Random Forest, Extreme Gradient Boosting (XGBoost), Support Vector Machine (SVM), and Multi-Layer Perceptron (MLP). Results: The prevalence of NAFLD was 50.22%. Among the machine learning models, Random Forest achieved the highest performance with an ROC AUC of 0.983 (95% CI: 0.952–0.999), followed by XGBoost at 0.977 (95% CI: 0.938–0.999) and MLP at 0.963 (95% CI: 0.915–0.995). SVM also showed strong performance with an AUC of 0.949 (95% CI: 0.897–0.985), while Logistic Regression demonstrated comparatively lower discrimination with an AUC of 0.886 (95% CI: 0.799–0.952). Key predictive features identified included platelet count, low-density lipoprotein (LDL), hemoglobin, and alanine aminotransferase (ALT). Logistic Regression highlighted platelet count as the most significant negative predictor, while LDL and ALT were positive contributors. Conclusions: This study shows the utility of ML in improving the identification and management of NAFLD in CHB patients, enabling targeted interventions. Future research should expand on these findings, integrating genetic and lifestyle factors to enhance predictive accuracy across diverse populations.